Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022 - Product Image

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022

  • ID: 4519910
  • Report
  • Region: Global
  • 116 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer
  • MORE
About Post-Traumatic Stress Disorder (PTSD) Therapeutics

(PTSD) Therapeutics include drugs that are used in the treatment of PTSD.

The analysts forecast the global post-traumatic stress disorder (PTSD) therapeutics market to grow at a CAGR of 1.26% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global post-traumatic stress disorder (PTSD) therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of post-traumatic stress disorder (PTSD) therapeutics.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck
Market drivers
  • Increasing initiatives by public and private organizations
  • For a full, detailed list, view the full report
Market challenges
  • Unmet need for existing therapies
  • For a full, detailed list, view the full report
Market trends
  • Emerging therapies for PTSD treatment
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE LANDSCAPE

PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY PRODUCT
  • Segmentation by product
  • Comparison by product
  • Antidepressants
  • Anxiolytics
  • Other PTSD therapeutics
  • Market opportunity by product
PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • PTSD therapeutics market in Americas
  • PTSD therapeutics market in EMEA
  • PTSD therapeutics market in APAC
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS
  • Emerging therapies for PTSD treatment
  • Increasing focus on clinical research by pharmaceutical companies and institutions
PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck
PART 16: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global CNS disorders therapeutics market segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Major pipeline products
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global PTSD therapeutics market - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global PTSD therapeutics market - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: Global PTSD therapeutics market - Market share 2017-2022 (%)
Exhibit 20: Comparison by product
Exhibit 21: Antidepressants market - Market size and forecast 2017-2022 ($ mn)
Exhibit 22: Antidepressants market - Year-over-year growth 2018-2022 (%)
Exhibit 23: Anxiolytics market - Market size and forecast 2017-2022 ($ mn)
Exhibit 24: Anxiolytics market - Year-over-year growth 2018-2022 (%)
Exhibit 25: Other PTSD therapeutics - Market size and forecast 2017-2022 ($ mn)
Exhibit 26: Other PTSD therapeutics - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by product
Exhibit 28: Customer landscape
Exhibit 29: Global PTSD therapeutics market - Market share by geography 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: PTSD therapeutics market in Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: PTSD therapeutics market in Americas - Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in Americas
Exhibit 34: PTSD therapeutics market in EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: PTSD therapeutics market in EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in EMEA
Exhibit 37: PTSD therapeutics market in APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 38: PTSD therapeutics market in APAC - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: GlaxoSmithKline - Overview
Exhibit 47: GlaxoSmithKline - Business segments
Exhibit 48: GlaxoSmithKline - Organizational developments
Exhibit 49: GlaxoSmithKline - Geographic focus
Exhibit 50: GlaxoSmithKline - Segment focus
Exhibit 51: GlaxoSmithKline - Key offerings
Exhibit 52: GlaxoSmithKline - Key customers
Exhibit 53: Pfizer - Overview
Exhibit 54: Pfizer - Business segments
Exhibit 55: Pfizer - Organizational developments
Exhibit 56: Pfizer - Geographic focus
Exhibit 57: Pfizer - Segment focus
Exhibit 58: Pfizer - Key offerings
Exhibit 59: Pfizer - Key customers
Exhibit 60: Eli Lilly and Company - Overview
Exhibit 61: Eli Lilly and Company - Business segments
Exhibit 62: Eli Lilly and Company - Organizational developments
Exhibit 63: Eli Lilly and Company - Geographic focus
Exhibit 64: Eli Lilly and Company - Segment focus
Exhibit 65: Eli Lilly and Company - Key offerings
Exhibit 66: Eli Lilly and Company - Key customers
Exhibit 67: H. Lundbeck - Overview
Exhibit 68: H. Lundbeck - Business segments
Exhibit 69: H. Lundbeck - Organizational developments
Exhibit 70: H. Lundbeck - Geographic focus
Exhibit 71: H. Lundbeck - Segment focus
Exhibit 72: H. Lundbeck - Key offerings
Exhibit 73: H. Lundbeck - Key customers
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Eli Lilly and Company
  • GlaxoSmithKline
  • H. Lundbeck
  • Pfizer
  • MORE
New Report Released: - Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022.

The author of the report recognizes the following companies as the key players in the global post-traumatic stress disorder (PTSD) therapeutics market: GlaxoSmithKline, Pfizer , Eli Lilly and Company, H. Lundbeck.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Emerging therapies for PTSD treatment Many pharmacologic agents are being tested as novel pharmacotherapies for PTSD. Some of the promising agents gaining increasing R&D focus include MDMA, ketamine, and glucocorticoids. MAPS is a non-profit research and educational organization that is funding the clinical trials of MDMA as a tool to assist psychotherapy for the treatment of PTSD. In its Phase II trial with 107 participants, it found that 61% of the participants are no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy, two months after the treatment. At the 12-month follow-up, 68% participants no longer had PTSD. All participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.”

According to the report, one of the major drivers for this market is Increasing initiatives by public and private organizations. Several public and private organizations are taking initiatives to raise awareness about PTSD and improve access to its treatment. For instance, to bring greater awareness about PTSD, the US Senate has designated June 27th as the national PTSD awareness day.

Further, the report states that one of the major factors hindering the growth of this market is Unmet need for existing therapies. The PTSD medications currently approved by the FDA for the treatment of PTSD (paroxetine and sertraline) do not improve the full range of its symptoms. They show little evidence of treatment effect in men and lack clinical evidence of efficacy in people whose traumatic event was combat-related and carry suicidality warnings. Furthermore, the approved SSRIs and SNRIs have been associated with mild to moderate side effects such as upset stomach, sweating, headache, dizziness, and sexual side effects such as decreased desire to have sex or difficulty in having an orgasm.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll